An observational study in Type II Diabetes, sponsored by Zhongda Hospital. Status unknown. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-08.
Sponsored by Zhongda Hospital · Observational
Study of the correlation between AGEsP and HbA1c and diabetic retinopathy prevalence: determination of cut-off value of AGEsP and HbA1c in type 2 diabetes diagnosis in China
To find the cut-off point of AGEsP and HbA1c for diagnosis of diabetes by drawing the logistic regression model between prevalence of retinopathy and AGEsP level and HbA1c level,and find the point where the prevalence of retinopathy changes most rapidly.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 6,000 is above the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Zhongda Hospital is the lead sponsor of 101 studies on the registry; 40 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Chinese natural population
Exclusion Criteria:
-
Physical examination, fundus examination, blood and urine samples collection
prevalence of retinopathy
the prevalence of retinopathy in different AGEsP and HbA1c levels
Time frame: 3 years
incidence of retinopathy
incidence of retinopathy in different AGEsP and HbA1c levels
Time frame: 3 years
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhongda Hospital